Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2022 | Circulating immune cell subsets in patients with melanoma from the OpACIN-neo trial

Rebecca Simpson, PhD, The University of Sydney, Sydney, Australia, provides an overview of an analysis of immune cells and related pathological responses in patients with stage III melanoma receiving ipilimumab and nivolumab in the Phase II OpACIN-neo trial (NCT02977052). Pre- and post-treatment peripheral blood mononuclear cells (PBMCs) were analyzed, which enabled the identification of differences in immune cells during treatment. This interview took place at the European Society for Medical Oncology (ESMO) 2022 Congress in Paris, France.